Binding Site is pleased to announce that the ground-breaking iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) study has reached an important milestone, with the publication of a paper outlining the design and recruitment of this population-based screening study.1
The large-scale study – which includes over 80,000 individuals, more than half of the eligible population of Iceland – aims to use a combination of blood-based testing, imaging, bone marrow sampling, and clinical questionnaires to improve our basic understanding of monoclonal gammopathy of undetermined significance (MGUS), which precedes multiple myeloma (MM).
